Sera Prognostics, Inc. (NASDAQ:SERA) Sees Significant Drop in Short Interest

Sera Prognostics, Inc. (NASDAQ:SERA) was the recipient of a large decline in short interest in January. As of January 15th, there was short interest totalling 844,400 shares, a decline of 19.6% from the December 31st total of 1,050,000 shares. Approximately 4.0% of the company’s stock are short sold. Based on an average trading volume of 102,700 shares, the days-to-cover ratio is currently 8.2 days.

Insider Buying and Selling

In related news, CEO Zhenya Lindgardt sold 12,075 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $7.32, for a total transaction of $88,389.00. Following the completion of the transaction, the chief executive officer now owns 819,758 shares in the company, valued at $6,000,628.56. The trade was a 1.45 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Paul Kearney sold 4,078 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $7.32, for a total transaction of $29,850.96. Following the transaction, the insider now owns 176,889 shares in the company, valued at $1,294,827.48. The trade was a 2.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 93,215 shares of company stock worth $666,835 in the last 90 days. 15.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Quest Partners LLC increased its stake in Sera Prognostics by 533.5% during the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after purchasing an additional 5,415 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Sera Prognostics in the 3rd quarter valued at $78,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Sera Prognostics in the 2nd quarter valued at $68,000. Prime Capital Investment Advisors LLC purchased a new stake in shares of Sera Prognostics in the 3rd quarter valued at $104,000. Finally, Pallas Capital Advisors LLC purchased a new stake in shares of Sera Prognostics in the 4th quarter valued at $113,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

Sera Prognostics Price Performance

Sera Prognostics stock traded down $1.20 during mid-day trading on Monday, reaching $5.27. 129,947 shares of the company traded hands, compared to its average volume of 102,104. Sera Prognostics has a fifty-two week low of $4.98 and a fifty-two week high of $12.35. The company has a market capitalization of $177.97 million, a price-to-earnings ratio of -5.32 and a beta of 0.81. The firm’s fifty day moving average is $7.36 and its two-hundred day moving average is $7.35.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same quarter last year, the firm earned ($0.23) EPS. As a group, equities research analysts predict that Sera Prognostics will post -0.96 earnings per share for the current year.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.